

Change to symptom control medication at the end of life; process flowchart

The purpose of this document is to record the agreed process for clinical review of the symptom control guidance for COVID 19. The guidance was developed based on palliative medicine consultant clinical experience (of non COVID conditions), local medication familiarity and safety, and nationally produced guidance for treatment of COVID in the secondary care setting.

Alternative medications have been considered in anticipation that there may be medication shortages. These have been reviewed by the palliative medicine consultant consortium, and then reviewed by the COVID EOL group.

